Correction: Long-term outcomes of early enzyme replacement therapy for mucopolysaccharidosis IV: Clinical case studies of two siblings (Diagnostics (2020) 10 (108) DOI: 10.3390/diagnostics10020108)

Abstract

The authors wish to make the following correction to this paper [1]: In the first paragraph of the Results section: “P1 and P2 started ERT with elosulfase alfa (VIMIZIM® by BioMarin©) 5 months post-diagnosis at age 4.5 years and 11 months, respectively, with an intravenous dose of 1.0 mg/kg/week.” The value of the dose is 1.0 mg/kg/week but should be corrected to 2.0 mg/kg/week. These changes have no material impact on the conclusions of our paper. We apologize to our readers.